Clinical trial · Observational
French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
French Assessment of Minimal Residual Disease by Liquid Biopsies in Pancreatic Ductal Adenocarcinoma Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice. Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence. Specifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after 1. curative-intended surgery and 2. adjuvant chemotherapy. FRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| ctDNA | — | UNRESOLVED | — |
| Liquid Biopsy | — | UNRESOLVED | — |
| Minimal Residual Disease | — | UNRESOLVED | — |
| Pancreatic Cancer Resectable | — | UNRESOLVED | — |
| Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample/Liquid Biopsy | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Pancreatic Ductal Adenocarcinoma patients
- description
- Resectable PDAC patients
- interventionNames
- Biological: Blood sample/Liquid Biopsy
Primary outcomes (1)
- measure
- 3-year Disease-free survival (DFS)
- timeFrame
- 3 years after the end of inclusion
- description
- Disease-free survival was defined as the time between the date of the baseline blood sampling/inclusion and the date of the first event among or recurrence or death from any cause.
Secondary outcomes (8)
- measure
- Sensitivity (Se) of the ctDNA diagnostics
- timeFrame
- 3 years after the end of inclusion
- description
- Sensitivity (Se) of the ctDNA diagnostics is calculated in subjects with a 3-year recurrence: Se = TP/(TP+FN) (a positive reference test)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pancreatic ductal adenocarcinoma, according to the assessment of the MDT. * Age 18 years or older. * Scheduled for curative intent surgical resection. Exclusion Criteria: * Hereditary pancreatic cancer. * Verified distant metastases. * Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and/or otherwise considered by the Investigator to be unlikely to complete the study. * Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening. * Pregnant or nursing woman, or in childbearing age and not willing to use contraception * Adult subject to a legal protection * Not covered by Health insurance * Patient unable to understand and sign written informed consent.
References
Publications (0)
Data not yet available